World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
31518
World Ranking
13547
National Ranking
6889

Shreyaskumar Patel publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Shreyaskumar Patel sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 400 publications — 38th percentile

38% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Shreyaskumar Patel D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Shreyaskumar Patel sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Shreyaskumar Patel is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on the field of Medicine, with a specialization spanning several subfields such as Pulmonary and Respiratory Medicine, Oncology, Cardiology and Cardiovascular Medicine, Pathology and Forensic Medicine, and Rheumatology.

The scientist's main topics of work concentrate on Sarcoma Diagnosis and Treatment, Cardiac tumors and thrombi, Vascular Tumors and Angiosarcomas, Bone Tumor Diagnosis and Treatments, CAR-T cell therapy research, Lymphoma Diagnosis and Treatment, and Gastrointestinal Tumor Research and Treatment.

Frequent publication venues for their work include:

  • Journal of Clinical Oncology
  • Cancers
  • Annals of Oncology
  • Clinical Cancer Research
  • Cancer

Some notable recent papers by Shreyaskumar Patel are:

  • Immuno-genomic landscape of osteosarcoma, 2020, Nature Communications
  • Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities, 2021, Cancer
  • Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network, 2020, Annals of Oncology
  • Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial, 2022, The Lancet Oncology
  • Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study, 2021, Journal of Clinical Oncology

Frequent co-authors collaborating with Patel include:

  • Anthony P. Conley
  • Alexander J. Lazar
  • Neeta Somaiah
  • J. Andrew Livingston
  • Ravin Ratan

Overall, the research profile of Shreyaskumar Patel reveals extensive engagement in oncology and related medical fields, especially focusing on tumor diagnosis and treatment modalities. Their work spans clinical, pathological, and therapeutic aspects of cancer subtypes, with a body of publications present in key oncology and cancer research outlets.

Best Publications

  • Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria

    Haesun Choi;Chuslip Charnsangavej;Silvana C. Faria;Homer A. Macapinlac

  • Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

    Ronald P. DeMatteo;Karla V. Ballman;Cristina R. Antonescu;Robert G. Maki

  • A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group.

    Charles G. Fisher;Christian P. Dipaola;Timothy C. Ryken;Mark H. Bilsky

  • Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

    Hussein A Tawbi;Melissa Burgess;Vanessa Bolejack;Brian A Van Tine

  • Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas

    Robert G. Maki;J. Kyle Wathen;Shreyaskumar R. Patel;Dennis A. Priebat

  • Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

    George D. Demetri;Margaret von Mehren;Robin L. Jones;Martee L. Hensley

  • Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

    Patrick Schöffski;Sant Chawla;Robert G. Maki;Antoine Italiano

  • We Should Desist Using RECIST, at Least in GIST

    Robert S. Benjamin;Haesun Choi;Homer A. Macapinlac;Michael A. Burgess

  • Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients.

    Gunar K. Zagars;Matthew T. Ballo;Peter W. T. Pisters;Raphael E. Pollock M.D.

  • Spinal Instability Neoplastic Score: An Analysis of Reliability and Validity From the Spine Oncology Study Group

    Daryl R. Fourney;Evan M. Frangou;Timothy C. Ryken;Christian P. DiPaola

  • Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: Primary tumor size and primary tumor location as prognostic indicators

    Montserrat Ayala-Ramirez;Lei Feng;Marcella M. Johnson;Shamim Ejaz

  • A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors

    Lei L. Chen;Jonathan C. Trent;Elsie F. Wu;Gregory N. Fuller

  • R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study

    Alberto S. Pappo;Shreyaskumar R. Patel;John Crowley;Denise K. Reinke

  • Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution.

    Charles A. Portera;Viet Ho;Shreyaskumar R. Patel;Kelly K. Hunt

  • Surgical Resection of Gastrointestinal Stromal Tumors After Treatment with Imatinib

    Robert H. I. Andtbacka;Chaan S. Ng;Courtney L. Scaife;Janice N. Cormier

  • Phase II Clinical Investigation of Gemcitabine in Advanced Soft Tissue Sarcomas and Window Evaluation of Dose Rate on Gemcitabine Triphosphate Accumulation

    Shreyaskumar R. Patel;Varsha Gandhi;Jan Jenkins;Nicholas Papadopolous

  • Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial

    Christopher L. Corless;Karla V. Ballman;Cristina R. Antonescu;Violetta Kolesnikova

  • High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.

    S R Patel;S Vadhan-Raj;N Papadopolous;C Plager

  • Optimizing Treatment of Desmoid Tumors

    Dina Lev;Dhanasekaran Kotilingam;Caimiao Wei;Matthew T. Ballo

  • Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer.

    Saroj Vadhan-Raj;Lesley J. Murray;Carlos Bueso-Ramos;Shreyaskumar Patel

Frequent Co-Authors

Robert S. Benjamin
Robert S. Benjamin The University of Texas MD Anderson Cancer Center
Raphael E. Pollock
Raphael E. Pollock The Ohio State University
Robert G. Maki
Robert G. Maki University of Pennsylvania
Alexander J. Lazar
Alexander J. Lazar The University of Texas MD Anderson Cancer Center
Barry W. Feig
Barry W. Feig The University of Texas MD Anderson Cancer Center
Peter W.T. Pisters
Peter W.T. Pisters The University of Texas MD Anderson Cancer Center
George D. Demetri
George D. Demetri Dana-Farber Cancer Institute
Margaret von Mehren
Margaret von Mehren Fox Chase Cancer Center
Gunar K. Zagars
Gunar K. Zagars The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
Funda Meric-Bernstam The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine isn’t limited to traditional MD routes. There are a range of related online degrees and certifications that offer flexibility and diverse healthcare career pathways. For example, nurses can advance their studies affordably through cheapest bsn to dnp programs, gaining advanced clinical and leadership skills while studying remotely.

Prospective pharmacists can explore pharmacy school online accredited options, which provide pathways to a Doctor of Pharmacy degree through rigorous yet convenient online programs. These accredited programs are vital for ensuring eligibility for licensure.

Not all healthcare roles require direct patient care. A bachelor of health information management online opens doors to data management and healthcare administration—a growing field as digital records become standard.

Those interested in the administrative side can consider medical coding and billing. Understanding medical billing and coding certification cost helps learners find cost-effective ways to enter this in-demand career.

Best Scientists Citing Shreyaskumar Patel

Trending Scientists

Recently Published Articles